JAC Advance Access published online on July 1, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh348
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Centre National de Référence Mycologie et Antifongiques, Institut Pasteur, Paris and Hôpital Necker, Paris, France
* To whom correspondence should be addressed. E-mail: raoul.herbrecht{at}chru-strasbourg.fr.
Objective: To study the pharmacoepidemiology of the prescription of systemic antifungal agents in 48 French haematology, intensive care and infectious diseases units. Patients and methods: Cases of invasive fungal infections (IFI) were identified retrospectively over a 1 year period. Data on underlying condition, IFI diagnosis, antifungal treatment and outcome were collected on the last five cases in each centre. Factors associated with first line therapy and with death were identified by multivariate analysis. Results: Two hundred and nine cases were included (102 aspergillosis, 86 candidiasis, 15 cryptococcosis). Amphotericin B, in different formulations, was the first line therapy in 60%, azoles in 32%, combinations in 8%. Haematological malignancies and neutropenia were associated with less frequent initial prescription of azoles [OR = 0.3 (0.1-0.8) and OR = 0.3 (0.1-0.9), respectively]. In aspergillosis, younger age and neutropenia were associated with less frequent initial prescription of azoles [OR = 0.03 (0.002-0.6) and OR = 0.09 (0.03-0.3), respectively] and previous history of IFI was associated with a higher probability of azole prescription [OR = 17.2 (2.4-124.3)]. In candidiasis, haematological malignancy and co-prescription of nephrotoxic agents were associated with a less frequent initial prescription of azoles [OR = 0.1 (0.04-0.4) and OR = 0.2 (0.06-0.9), respectively]. Three factors were associated with a lower risk of death: cryptococcosis [OR = 0.16 (0.03-0.98)], hospitalization in infectious diseases units [OR = 0.40 (0.16-0.97)] and recent surgery [OR = 0.26 (0.08-0.80)]. Severe renal insufficiency was associated with a higher probability of death [OR = 8.77 (1.97-38.97)]. Conclusions: Our results emphasize factors associated with the antifungal therapeutic decision and with the outcome of IFI.
Revised May 26, 2004
Accepted June 3, 2004
Original article
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999
2 Cemka-Eval, Bourg la Reine, France
3 Centre Hospitalier Universitaire de Tours, Paris, France
4 Hôpital Européen Georges Pompidou, Paris, France
5 Hôpital Pitié-Salpêtrière, Paris, France
6 Hôpital de Ravenel, Mirecourt, France
7 Hôpital de la Timone, Marseille, France
8 Hôpital Saint-Antoine, Paris, France
9 Centre Hospitalier Universitaire de Rouen, France
10 Département d'Hématologie et d'Oncologie, Hôpital Hautepierre, Avenue Molière, 67098 Strasbourg and the French Cooperative Study Group, France
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]
|
|